Metagenomi Therapeutics Files Corporate Presentation under Reg FD

What Happened Metagenomi Therapeutics, Inc. announced via Form 8-K (filed September 22, 2026) that it has furnished its September 2026 corporate presentation as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The presentation is incorporated by reference into the filing. The report was signed by President and CEO Jian Irish, Ph.D., M.B.A., dated September 21, 2026.

Key Details

• Filing date: September 22, 2026 (Form 8-K, Accession No. 0001193125-26-397037).
• Item reported: 7.01 Regulation FD Disclosure — corporate presentation furnished as Exhibit 99.1.
• Signature: Signed by Jian Irish, President and CEO, dated September 21, 2026.
• The filing does not disclose earnings, executive changes, mergers, or other material transactions.

Why It Matters Furnishing a corporate presentation under Regulation FD means Metagenomi is publicly sharing information it considers material so all investors have access at the same time. Investors should review Exhibit 99.1 (available on the SEC EDGAR site) for updates on the company’s strategy, pipeline, or corporate outlook. This 8-K is a disclosure of presentation materials only, not a financial results or management-change filing.